mGluR5 Positive Allosteric Modulation as a Novel Therapeutic Target for the Cognitive Deficits Associated with Schizophrenia

abstract: Patients with schizophrenia have impaired cognitive flexibility, as evidenced by behaviors of perseveration. Cognitive impairments may be due to dysregulation of glutamate and/or loss of neuronal plasticity in the medial prefrontal cortex (mPFC). The purpose of these studies was to examine...

Full description

Bibliographic Details
Other Authors: LaCrosse, Amber (Author)
Format: Doctoral Thesis
Language:English
Published: 2014
Subjects:
Online Access:http://hdl.handle.net/2286/R.I.25905
id ndltd-asu.edu-item-25905
record_format oai_dc
spelling ndltd-asu.edu-item-259052018-06-22T03:05:26Z mGluR5 Positive Allosteric Modulation as a Novel Therapeutic Target for the Cognitive Deficits Associated with Schizophrenia abstract: Patients with schizophrenia have impaired cognitive flexibility, as evidenced by behaviors of perseveration. Cognitive impairments may be due to dysregulation of glutamate and/or loss of neuronal plasticity in the medial prefrontal cortex (mPFC). The purpose of these studies was to examine the effects of mGluR5 positive allosteric modulators (PAMs) alone and in combination with the NMDAR antagonist MK-801, a pharmacological model of schizophrenia. An operant-based cognitive set-shifting task was utilized to assess cognitive flexibility, in vivo microdialysis procedures to measure extracellular glutamate levels in the mPFC, and diolistic labeling to assess the effects on dendritic spine density and morphology in the mPFC. Results revealed that chronic administration of the mGluR5 PAM CDPPB was able to significantly reduce the effects of chronically administered MK-801 on both behavioral perseveration and glutamate neurotransmission. Results also showed that CDPPB had no evidence of an effect on dendritic spine density or morphology, but the mGluR5 negative allosteric modulator fenobam caused significant increases in spine density and the frequency of occurrence of spines with smaller head diameters. Conclusions include that CDPPB is able to reverse MK-801 induced cognitive deficits as well as alterations in mPFC glutamate neurochemistry. The culmination of these studies add further support for targeting mGluR5 with PAMs as a novel mechanism to alleviate cognitive impairments in patients with schizophrenia. Dissertation/Thesis LaCrosse, Amber (Author) Olive, Michael (Advisor) Olive, Michael (Committee member) Gallitano-Mendel, Amelia (Committee member) Sanabria, Federico (Committee member) Hammer, Ronald (Committee member) Arizona State University (Publisher) Neurosciences Psychology Behavior Cognitive Dendrite Microdialysis Schizophrenia Treatments eng 187 pages Doctoral Dissertation Psychology 2014 Doctoral Dissertation http://hdl.handle.net/2286/R.I.25905 http://rightsstatements.org/vocab/InC/1.0/ All Rights Reserved 2014
collection NDLTD
language English
format Doctoral Thesis
sources NDLTD
topic Neurosciences
Psychology
Behavior
Cognitive
Dendrite
Microdialysis
Schizophrenia
Treatments
spellingShingle Neurosciences
Psychology
Behavior
Cognitive
Dendrite
Microdialysis
Schizophrenia
Treatments
mGluR5 Positive Allosteric Modulation as a Novel Therapeutic Target for the Cognitive Deficits Associated with Schizophrenia
description abstract: Patients with schizophrenia have impaired cognitive flexibility, as evidenced by behaviors of perseveration. Cognitive impairments may be due to dysregulation of glutamate and/or loss of neuronal plasticity in the medial prefrontal cortex (mPFC). The purpose of these studies was to examine the effects of mGluR5 positive allosteric modulators (PAMs) alone and in combination with the NMDAR antagonist MK-801, a pharmacological model of schizophrenia. An operant-based cognitive set-shifting task was utilized to assess cognitive flexibility, in vivo microdialysis procedures to measure extracellular glutamate levels in the mPFC, and diolistic labeling to assess the effects on dendritic spine density and morphology in the mPFC. Results revealed that chronic administration of the mGluR5 PAM CDPPB was able to significantly reduce the effects of chronically administered MK-801 on both behavioral perseveration and glutamate neurotransmission. Results also showed that CDPPB had no evidence of an effect on dendritic spine density or morphology, but the mGluR5 negative allosteric modulator fenobam caused significant increases in spine density and the frequency of occurrence of spines with smaller head diameters. Conclusions include that CDPPB is able to reverse MK-801 induced cognitive deficits as well as alterations in mPFC glutamate neurochemistry. The culmination of these studies add further support for targeting mGluR5 with PAMs as a novel mechanism to alleviate cognitive impairments in patients with schizophrenia. === Dissertation/Thesis === Doctoral Dissertation Psychology 2014
author2 LaCrosse, Amber (Author)
author_facet LaCrosse, Amber (Author)
title mGluR5 Positive Allosteric Modulation as a Novel Therapeutic Target for the Cognitive Deficits Associated with Schizophrenia
title_short mGluR5 Positive Allosteric Modulation as a Novel Therapeutic Target for the Cognitive Deficits Associated with Schizophrenia
title_full mGluR5 Positive Allosteric Modulation as a Novel Therapeutic Target for the Cognitive Deficits Associated with Schizophrenia
title_fullStr mGluR5 Positive Allosteric Modulation as a Novel Therapeutic Target for the Cognitive Deficits Associated with Schizophrenia
title_full_unstemmed mGluR5 Positive Allosteric Modulation as a Novel Therapeutic Target for the Cognitive Deficits Associated with Schizophrenia
title_sort mglur5 positive allosteric modulation as a novel therapeutic target for the cognitive deficits associated with schizophrenia
publishDate 2014
url http://hdl.handle.net/2286/R.I.25905
_version_ 1718700512181747712